Main > NEPHROLOGY > USA. C. ANCA Vesculitis>Treat.>

---

USA. C. ANCA Vesculitis>Treat.>'s subsections
(*) EU CE Mark Date: 2022. 01.19
(*) JP Approval Date: 2021. 09.27.
(*) USA Approval Date: 2021. 10.08
>Selective C5AR Inhibitor Capsules
ANCA: anti-neutrophil cytoplasmic>
AutoImmune Disease
C5AR: Complement 5A Receptor
Company Licensee Ex JP & USA:
Company Licensee JP:
Company Licensor:
Generic Name: Avacopan
Patent>Assignee; Claims; No.; Etc.
Patent>Total USA No.: 11
Patent>UpDate: 2021. 09.28
Product Web-Site USA

USA. C. ANCA Vesculitis>Treat.>'s products
This section has no products